Close Menu

Proteomics International

The partners are developing a new lab that will focus on research into protein biomarkers with medical, agricultural, and environmental applications.

The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

Proteomics International's PromarkerD will be tested in clinical studies alongside Dimerix's investigational chronic kidney disease drug DMX-200.

The company said it will use the funds to commercialize its proteomic PromarkerD kidney disease test and launch an analytical testing service business.

Named PromarkerD, the test is intended to predict risk of developing kidney disease in diabetics and diagnose patients with diabetic kidney disease.

The Australian company has also inked a deal to launch its proteomics-based kidney disease test in China. 

The firm seeks to raise between A$4 million and A$6 million through an offering of up to 30 million shares of its stock at A$.20 per share.

NEW YORK (GenomeWeb News) – Proteomics International recently announced an agreement with inVentiv Health Clinical aimed at the development of biosimilars.

Exact Sciences' shareholders have re-elected three members of its board of directors, including company President and CEO Kevin Conroy, as well as Katherine Napier, and David Thompson.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.